Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Operating Leases (2021 - 2025)

TransMedics has reported Operating Leases over the past 5 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Operating Leases at $3.6 million for Q4 2025, down 42.76% from a year ago — trailing twelve months through Dec 2025 was $3.6 million (down 42.76% YoY), and the annual figure for FY2025 was $3.6 million, down 42.76%.
  • Operating Leases for Q4 2025 was $3.6 million at TransMedics, down from $4.4 million in the prior quarter.
  • Over the last five years, Operating Leases for TMDX hit a ceiling of $8.6 million in Q4 2021 and a floor of $3.6 million in Q4 2025.
  • Median Operating Leases over the past 5 years was $7.2 million (2024), compared with a mean of $6.9 million.
  • Biggest five-year swings in Operating Leases: increased 5.71% in 2023 and later tumbled 42.76% in 2025.
  • TransMedics' Operating Leases stood at $8.6 million in 2021, then dropped by 13.82% to $7.4 million in 2022, then grew by 3.94% to $7.7 million in 2023, then fell by 18.92% to $6.2 million in 2024, then tumbled by 42.76% to $3.6 million in 2025.
  • The last three reported values for Operating Leases were $3.6 million (Q4 2025), $4.4 million (Q3 2025), and $4.9 million (Q2 2025) per Business Quant data.